Question

Drug of choice: Ilumya (tildrakizumab-asmn)

1. For this drug, determine the classification of the drug. If it is a combination drug, what are the classifications of each of the two combined drugs?

2. If it is a combination drug, what was the purpose of combining them?

3. Describe the classification(s)— uses/implications, pharmacodynamics, pharmacokinetics, safe dosage range(s), general side effects, concerns or warnings of using this drug and your drug specifically. If it is a combined drug, discuss both of the drugs.

4. Determine what made this drug different than the others in the class---what hole did it fill?

5. What concerns do you have with giving this drug? In your practice, what would you want to assess in your patient who is taking this drug? If your family member was taking this drug, what would you want to tell them about this drug?

Answer 1

Ilumya drug is mainly used in adults with moderate plaque psoriasis.

1.ilumya drugs is mainly belongs to the classification of skin and mucus membrane agents.Ilumya not a combination drug. its active ingredient is tildrakizumab-asmn.

3. tildrakizumab-asmn is a humanized IgG1/k antibody that specifically binds to the p19 subunit of interleukin-23 (IL-23). Tildrakizumab-asmn is produced in a recombinant Chinese hamster ovary (CHO) cell line and has an approximate molecular mass of 147 kilodaltons

active ingredients:tildrakuzumab-asmn

inactive ingredients:L-histidine.L-histidine hydrochloride monohydrate,polysorbate 80,sucrose and water for injection

pharmacodynamics: there is no formal pharmacodynamics studies have been conducted yet with ilumya

pharmacokinetics:

Tildrakizumab pharmacokinetics increases proportionally over a dose range from 50 mg to 200 mg following subcutaneous administration in subjects. Steady-state concentrations were achieved by Week 16 following subcutaneous administration of tildrakizumab at Weeks 0, 4, and every 12 weeks thereafter. At the 100 mg dose at Week 16, the mean (± SD) steady-state trough concentrations ranged from 1.22 ± 0.94 mcg/mL to 1.47 ± 1.12 mcg/mL. The geometric mean (CV%) steady-state Cmax was 8.1 mcg/mL (34%).

Absorption

The absolute bioavailability of tildrakizumab was estimated to be 73-80% following subcutaneous injection.

Distribution

The geometric mean (CV%) volume of distribution is 10.8 L (24%).

Elimination

The geometric mean (CV%) systemic clearance was 0.32 L/day (38%) and the half-life was approximately 23 days (23%).

side effects:

• diarrhea
• injection site infections like itching redness pain inflammation etc
• upper respiratory tract infection

4.tildrakizumab-asmn belongs to special category of drugs which can ccure cancer,autoimmune diseases and other skin infections

5.

1. ilumya should only given by healthcare provider
2. its a type of subcutaneous injection given in upper arms, thighs and stomach area
3. it can cause serious allergic reactions
4. check for TB before starting the treatment with ilumya
5. avoid in case of pregnancy or planing to get pregnant, breastfeeding mothers